Although the mechanisms how increased systemic IgA and/or reduced intestinal SIgA are involved in disease development and progression are not clear yet, some gut dysbiosis and bacterial overgrowth observed in ALD and NAFLD/NASH might contribute to decreased SIgA levels in the gut. The gene discussed is CD79A; the disease is metabolic dysfunction-associated steatotic liver disease.